Drug
Fibroblast Growth Factor 7 clinical trials
Also written Palifermin.
- studies test it
- 43
- open now
- 6
- in phase 3
- 8
- first study started
- 2000
Keep track of what changes. Save the Fibroblast Growth Factor 7 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
42 studies that test it; most in 2005 (9)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 1 |
| 2005 | 9 |
| 2006 | 5 |
| 2007 | 4 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 4 |
| 2012 | 3 |
| 2015 | 3 |
| 2020 | 1 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 20
- Phase 2
- 25
- Phase 3
- 8
- Phase 4
- 1
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 29
Swedish Orphan Biovitrum (11) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Amgen (3) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (1) · University College, London (1) · University of Arizona (1) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Busulfan (8) · Melphalan (5) · Fludarabine (4) · Alemtuzumab (4) · Filgrastim (3) · Rituximab (2) · Etoposide (2) · Antilymphocyte Serum (2)
Studies
Open first, then newest update. How each study uses Fibroblast Growth Factor 7 is read from its arms, and is right about nine times in ten.
Testing it · 43
- Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIMEnrolling by invitationPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT07775313Written as Palifermin
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)RecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT01306019Written as Palifermin
- Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene TherapyEnrolling by invitationPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT06851767Written as Palifermin
- Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous DiseaseRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT06325709Written as Palifermin
- Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient StudyRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT06959771Written as Palifermin
- Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn DiseaseNot yet recruitingPhase 1/2Stanford UniversityNCT06986382Written as Palifermin
- Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell TransplantationCompletedPhase 1/2National Cancer Institute (NCI)NCT02356159Written as Palifermin
- Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedUniversity College, LondonNCT01085617Written as palifermin
- Keratinocyte Growth Factor- Hair Serum for the Prevention of Chemotherapy Induced AlopeciaCompletedEarly Phase 1University of ArizonaNCT04554732Written as Keratinocyte growth factor
- Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected AdultsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00376935Written as Palifermin
- Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)CompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00629798Written as Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant
- Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)TerminatedEarly Phase 1Columbia UniversityNCT00881556Written as Palifermin
- Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined ImmunodeficiencyStatus unknownPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT03315078Written as Palifermin
- Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple SclerosisTerminatedPhase 1/2Cambridge University Hospitals NHS Foundation TrustNCT01712945Written as Palifermin
- Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell TransplantWithdrawnPhase 2Children's Oncology GroupNCT00728585Written as Palifermin
- Phase 2 Haplotype Mismatched HSCT in Patients With Hematological MalignanciesTerminatedPhase 2Sherif S. FaragNCT00593554Written as Palifermin
- Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck CancerTerminatedPhase 3Radiation Therapy Oncology GroupNCT00360971Written as palifermin
- A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid TumorsTerminatedEarly Phase 1Montefiore Medical CenterNCT02653196Written as Keratinocyte Growth Factor
- A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent ChemotherapyCompletedPhase 1/2Swedish Orphan BiovitrumNCT00626639Written as palifermin
- Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 2Swedish Orphan BiovitrumNCT00094861Written as Palifermin
See all 43 studies that test Fibroblast Growth Factor 7 →
Given in every arm · 14 — Fibroblast Growth Factor 7 is usual care beside what is tested
- Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic SyndromeRecruitingPhase 2City of Hope Medical CenterNCT07582172Written as Palifermin
- Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell TransplantActive, not recruitingPhase 1City of Hope Medical CenterNCT04177004Written as Palifermin
- 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic SyndromeActive, not recruitingPhase 1City of Hope Medical CenterNCT05139004Written as Palifermin
- Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell TransplantationActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT01746849Written as Palifermin
- CHOEP + High Dose Therapy + Auto SCT for T-Cell LymphomaTerminatedPhase 2Dana-Farber Cancer InstituteNCT01746173Written as Palifermin
- High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk MyelomaCompletedPhase 2M.D. Anderson Cancer CenterNCT01237951Written as Palifermin
- High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's DiseaseCompletedPhase 2M.D. Anderson Cancer CenterNCT01200329Written as Palifermin
- Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC SubtypeTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT02589145Written as Palifermin
- Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell TransplantWithdrawnPhase 1City of Hope Medical CenterNCT03531281Written as Palifermin
- Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple MyelomaWithdrawnPhase 1/2City of Hope Medical CenterNCT03100877Written as Palifermin
- Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed LymphomaWithdrawnPhase 2M.D. Anderson Cancer CenterNCT02961816Written as Palifermin
- Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid MalignanciesCompletedPhase 1M.D. Anderson Cancer CenterNCT00410982Written as Palifermin
- Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid MalignanciesCompletedPhase 1M.D. Anderson Cancer CenterNCT01421173Written as Palifermin
- Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in MyelomaWithdrawnPhase 2M.D. Anderson Cancer CenterNCT02114502Written as Palifermin
Codes
What other systems call Fibroblast Growth Factor 7 · ClinicalTrials.gg INT008873
- RxNorm 196319One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| RxNorm | 196319 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.